Engineered zinc finger protein transcription factors show promise in Huntington’s disease research by selectively repressing mutant HTT, affirms an article published by Perking Elmer last Thursday, October 7.
Perking Elmer informs that researchers from CHDI Foundation and Sangamo Therapeutics believe the ideal therapeutic will be one that completely eliminates the expression of mHTT without interfering with normal HTT function. In an effort to do just that -the company says-, “they have engineered zinc finger protein transcription factors (ZFP-TFs) to target the pathogenic CAG repeat and selectively lower mHTT as a therapeutic strategy. The article features Dr. Bryan Zeitler, lead scientist at Sangamo Biosciences, and Ignacio Muñoz-Sanjuán, senior author from CHDI Foundation.
The ideal therapeutic will be one that completely eliminates the expression of mHTT
without interfering with normal HTT function.Ignacio Muñoz-Sanjuan
To read the full article please click HERE.
Source: PerkinElmer Website